Key points are not available for this paper at this time.
Fifteen years ago, an omic study of medulloblastoma revealed the existence of four groups that are biologically and clinically different. Since then, various molecular classification methods have emerged, each with different diagnostic capabilities. Knowledge of these tools is essential for countries with low economic resources to be able to access the technology that is most within their reach since, at present, the precision of molecular classification is crucial for clinical practice, not only because of its relevance in the prognosis of patients but also because of its decisive impact on therapeutic strategies, which are essential for reducing mortality from this disease.
Ramírez‐Chiquito et al. (Fri,) studied this question.